share_log

AlloVir Analyst Ratings

Benzinga ·  Aug 7, 2023 22:56
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/07/2023 553.59% Morgan Stanley $20 → $20 Reiterates Overweight → Overweight
04/26/2023 520.92% SVB Securities $16 → $19 Maintains Outperform
01/27/2023 553.59% Morgan Stanley $27 → $20 Maintains Overweight
01/23/2023 520.92% SVB Leerink $25 → $19 Maintains Outperform
11/07/2022 716.99% SVB Leerink $24 → $25 Maintains Outperform
09/09/2022 782.35% Morgan Stanley $32 → $27 Maintains Overweight
07/28/2022 651.63% SVB Leerink $30 → $23 Maintains Outperform
05/19/2022 1011.11% Piper Sandler $55 → $34 Maintains Overweight
02/10/2022 880.39% SVB Leerink $32 → $30 Maintains Outperform
01/18/2022 1370.59% Morgan Stanley $48 → $45 Maintains Overweight
12/17/2021 945.75% SVB Leerink $37 → $32 Maintains Outperform
11/08/2021 1109.15% SVB Leerink $41 → $37 Maintains Outperform
10/12/2021 1468.63% Morgan Stanley $47 → $48 Maintains Overweight
09/29/2021 7252.94% Morgan Stanley $175 → $225 Maintains Overweight
08/18/2021 1435.95% Morgan Stanley $50 → $47 Maintains Overweight
05/06/2021 1272.55% SVB Leerink $41 → $42 Maintains Outperform
04/19/2021 1533.99% Morgan Stanley $49 → $50 Maintains Overweight
08/24/2020 1533.99% JP Morgan → $50 Initiates Coverage On → Overweight
08/24/2020 1501.31% Morgan Stanley → $49 Initiates Coverage On → Overweight
08/24/2020 1239.87% SVB Leerink → $41 Initiates Coverage On → Outperform

What is the target price for AlloVir (ALVR)?

The latest price target for AlloVir (NASDAQ: ALVR) was reported by Morgan Stanley on August 7, 2023. The analyst firm set a price target for $20.00 expecting ALVR to rise to within 12 months (a possible 553.59% upside). 6 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for AlloVir (ALVR)?

The latest analyst rating for AlloVir (NASDAQ: ALVR) was provided by Morgan Stanley, and AlloVir reiterated their overweight rating.

When is the next analyst rating going to be posted or updated for AlloVir (ALVR)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AlloVir, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AlloVir was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

Is the Analyst Rating AlloVir (ALVR) correct?

While ratings are subjective and will change, the latest AlloVir (ALVR) rating was a reiterated with a price target of $20.00 to $20.00. The current price AlloVir (ALVR) is trading at is $3.06, which is out of the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment